{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', '11.', 'SUPPORTING DOCUMENTATION AND OPERATIONAL', 'CONSIDERATIONS', '11.1.', 'Appendix 1: Abbreviations and Trademarks', 'Abbreviations', '3TC', 'Lamivudine, EPIVIR', 'ABC', 'Abacavir, ZIAGEN', 'ABC/3TC', 'Abacavir/lamivudine, EPZICOM, KIVEXA', 'AE', 'Adverse event', 'AIDS', 'Acquired immunodeficiency syndrome', 'ALT', 'Alanine aminotransferase', 'Anti-HBc', 'Hepatitis B Core Antibody', 'ARV', 'Antiretroviral', 'ART', 'Antiretroviral therapy', 'ATV', 'Atazanavir', 'ATV/r', 'Atazanavir/ritonavir', 'AST', 'Aspartate aminotransferase', 'AUC', 'Area under the curve', 'BMI', 'Body Mass Index', 'BUN', 'Blood Urea Nitrogen', 'c/mL', 'Copies/milliliter', 'CAR', 'Current ART regimen', 'cART', 'Combination ART', 'CDC', 'Centers for Disease Control and Prevention', 'CKD-EPI', 'Chronic Kidney Disease Epidemiology Collaboration', 'Cmax', 'Maximum concentration', 'CMH', 'Cochran-Mantel Haenszel', 'CRF', 'Case Report Form', 'CI', 'Confidence interval', 'ConART', 'Concomitant ART therapy', 'CONSORT', 'Consolidated Standards of Reporting Trials', 'CPK', 'Creatine phosphokinase', 'CV', 'Cardiovascular', 'CVW', 'Confirmed Virologic Withdrawal', 'DAIDS', 'Division of Acquired Immunodeficiency Syndrome', 'DDI', 'Drug-Drug Interaction', 'DILI', 'Drug induced liver injury', 'DNA', 'Deoxyribonucleic acid', 'DTG', 'Dolutegravir, TIVICAY', 'E/C/F/TAF', 'Elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide', 'ECG', 'Electrocardiogram', 'eCRF', 'Electronic case report form', 'eC-SSRS', 'Electronic Columbia Suicidality Severity Rating Scale', 'EFV', 'Efavirenz', '86']['2017N331008_06', 'CONFIDENTIAL', '208090', 'eGFR', 'Estimated glomerular filtration rate', 'EVG', 'Elvitegravir', 'FDA', 'Food and Drug Administration', 'FDC', 'Fixed-dose combination', 'FTC', 'Emtricitabine', 'GCP', 'Good Clinical Practice', 'GCSP', \"GSK's Global Clinical Safety and Pharmacovigilance\", 'GSK', 'GlaxoSmithKline', 'GFR', 'Glomerular Filtration rate', 'HAART', 'Highly active ART therapy', 'HbA1c', 'Glycated hemoglobin', 'HBsAg', 'Hepatitis B surface Antigen', 'HBV', 'Hepatitis B virus', 'hCG', 'Human chorionic gonadotropin', 'HCV', 'Hepatitis C virus', 'HDL', 'High density lipoprotein', 'HDPE', 'High density polyethylene', 'HIV', 'Human immunodeficiency virus', 'HIV TSQ', 'HIV treatment satisfaction questionnaire', 'HLA', 'Human leukocyte antigen', 'HOMA-IR', 'Homeostasis model of assessment - insulin resistance', 'HSR', 'Hypersensitivity reaction', 'IB', \"Investigator's Brochure\", 'ICH', 'International Conference on Harmonisation of Technical', 'Requirements for Pharmaceuticals for Human Use', 'IDMC', 'Independent data monitoring committee', 'IEC', 'Independent Ethics Committee', 'IgG', 'Immunoglobulin G', 'IgM', 'Immunoglobulin M', 'IL', 'Interleukin', 'INI', 'Integrase inhibitor', 'INSTI', 'Integrase strand transfer inhibitor', 'INR', 'International normalized ratio', 'IP', 'Investigational Product', 'IRB', 'Institutional Review Board', 'ITT-E', 'Intent-to-treat exposed', 'IUD', 'Intrauterine device', 'IVRS/IWRS', 'Interactive Voice/Web Recognition System', 'LDL', 'Low density lipoprotein', 'LPV', 'Lopinavir', 'MCH', 'Mean corpuscular hemoglobin', 'MCV', 'Mean corpuscular volume', 'MedDRA', 'Medical dictionary for regulatory activities', 'Mg', 'Milligram', 'Mg/dL', 'Milligram per deciliter', 'm-ITT', 'Modified Intent to Treat', '87']\n\n###\n\n", "completion": "END"}